 |
|
|
| |
Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4
|
| |
| |
Download the PDF here
webcast:
http://www.croiwebcasts.org/console/player/25809?mediaType=slideVideo&
Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
Susanna Naggie1, Curtis Cooper2, Michael Saag3, Luisa M. Stamm4, Jenny C. Yang4, Phillip S. Pang4, John G. McHutchison4, Douglas Dieterich5, Mark Sulkowski6
1Duke Clinical Research Institute, Durham, NC; 2University of Ottawa, The Ottawa Hospital, Ottawa, ON; 3University of Alabama at Birmingham, Birmingham, AL;
4Gilead Sciences, Inc., Foster City, CA; 5Icahn School of Medicine at Mount Sinai, New York, NY; 6Johns Hopkins University School of Medicine, Baltimore, MD
After this oral presentation during Q&A the question was raised regarding African-Americans, why was their SVR rate lower at 90% than overall group of 96%. The speaker said they did PK sampling on blacks on EFV & there were not lower LDV levels, so there is no apparent explanation, it was mentioned many of these pts had prior Peg/Rbv experience, were TT and over 7% of prior treat-exp in study were nulls. On the surface each of these explanations taken singularly should not explain the outcome, it is possible this outcome was a quirk, Naggie the author also said we need larger more powered studies in African-Americans.
|
| |
|
|
|
|
|
